Proceeds expected to support the upcoming planned launches and fund the continued development of Niktimvo and revumenibExpected to fund Syndax through profitability; proforma cash approaching $800 million as of June 30 NEW YORK and WALTHAM, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) and Syndax Pharmaceuticals (Nasdaq: SNDX) today announced that Royalty Pharma has entered into a $350 million synthetic royalty funding agreement with Syndax based on U.S. net sales of Niktimvo (a ...

In its upcoming report, Royalty Pharma (RPRX) is predicted by Wall Street analysts to post quarterly earnings of $0.95 per share, reflecting an increase of 20.3% compared to the same period last year. Revenues are forecasted to be $710.89 million, representing a year-over-year increase of 11.6%.Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted upward by 0.5% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections d ...

NEW YORK, Oct. 16, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2024 financial results on Wednesday, November 6, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day. Conference Call Information Please visit the "Investors" page of the company's website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to vi ...

NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2024 of $0.21 per Class A ordinary share. The dividend will be paid on December 10, 2024, to shareholders of record at the close of business on November 15, 2024. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, c ...

Core Viewpoint - Royalty Pharma (RPRX) has received an upgrade to a Zacks Rank 2 (Buy) due to an upward trend in earnings estimates, which is a significant factor influencing stock prices [1][3]. Earnings Estimates and Stock Price Movement - The Zacks rating system emphasizes the importance of changing earnings estimates in determining stock price movements, with a strong correlation observed between earnings estimate revisions and near-term stock performance [4][6]. - Institutional investors play a role in this relationship, as they adjust their valuations based on earnings estimates, leading to stock price fluctuations through large transactions [4]. Company Performance and Outlook - The upgrade for Royalty Pharma indicates an improvement in the company's underlying business, which is expected to positively influence its stock price [5]. - Analysts have raised their earnings estimates for Royalty Pharma, with the Zacks Consensus Estimate for the fiscal year ending December 2024 projected at $4.04 per share, reflecting a year-over-year change of -10% [8]. Zacks Rank System - The Zacks Rank system categorizes stocks into five groups based on earnings estimates, with a proven track record of Zacks Rank 1 stocks generating an average annual return of +25% since 1988 [7]. - Royalty Pharma's upgrade to Zacks Rank 2 places it in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [10].

With their high yields and strong underlying businesses, these stocks are hard to pass up. You don't have to be rich to begin generating passive income. Now that nearly all online stock brokers have eliminated deposit requirements and minimum fees to enact common stock trades, almost anyone can afford to put some money to work. Right now, $100 is more than enough to buy shares of AT&T (T 0.46%), and Royalty Pharma (RPRX 0.28%). If you have cash ready to invest that you won't need to pay bills or cover unfor ...

Group 1: Western Union - Western Union's stock has decreased by over 50% since its peak in 2020, with a current dividend yield of 7.9% [3][4] - The company processed 293.2 million consumer money transfer transactions in the second quarter, a 4% year-over-year increase, but only a slight rise from 2019 [3][4] - Revenue fell by 9% year-over-year in the second quarter, impacted by a 7% decline in revenue due to Iraq's ban on dollar transactions [4][7] - Western Union is losing market share to competitors like Wise, which reported an 18% increase in transfer volume [6] - The stock is trading at a low valuation of 7.4 times trailing earnings, but earnings are declining as market competition increases [8] Group 2: Royalty Pharma - Royalty Pharma operates as a specialized lender in the biopharmaceutical industry, currently offering a 3% dividend yield [9] - The company has seen portfolio receipts grow by 13% annually from 2010 to 2020, with a 12% year-over-year increase to $608 million in the second quarter [10][11] - Royalty Pharma has raised its quarterly payout by 40% since initiating dividends in 2020 and plans to invest $2 billion in acquiring royalties in 2024 [11] - The company is trading at 18.6 times trailing earnings, which is considered low for its double-digit growth rate [12]

Core Insights - Royalty Pharma and Ascendis Pharma have entered into a $150 million capped synthetic royalty funding agreement based on U.S. net sales of Yorvipath, the first FDA-approved treatment for hypoparathyroidism in adults [1][2] Group 1: Agreement Details - Ascendis Pharma will receive an upfront payment of $150 million in exchange for a 3% royalty on U.S. net sales of Yorvipath [2] - Royalty payments to Royalty Pharma will cease upon reaching a multiple of 2.0x, or 1.65x if royalties are received by December 31, 2029 [2] Group 2: Company Profiles - Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the biopharmaceutical industry, with a portfolio that includes royalties on over 35 commercial products [4] - Ascendis Pharma focuses on developing new therapies using its innovative TransCon technology platform, aiming to make a meaningful difference in patients' lives [5]

Core Viewpoint - Royalty Pharma reported quarterly earnings of $0.96 per share, exceeding the Zacks Consensus Estimate of $0.95 per share, and showing an increase from $0.85 per share a year ago, indicating a positive earnings surprise of 1.05% [1] Financial Performance - The company achieved revenues of $608 million for the quarter ended June 2024, surpassing the Zacks Consensus Estimate by 1.19% and up from $545 million in the same quarter last year [2] - Over the last four quarters, Royalty Pharma has exceeded consensus EPS estimates three times and has also topped consensus revenue estimates three times [2] Stock Performance and Outlook - Royalty Pharma shares have declined approximately 3% since the beginning of the year, contrasting with the S&P 500's gain of 9% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the revisions of earnings estimates [3][4] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is $0.91, with expected revenues of $670.03 million, and for the current fiscal year, the consensus EPS estimate is $3.96 on revenues of $2.68 billion [7] Industry Context - The Financial - Miscellaneous Services industry, to which Royalty Pharma belongs, is currently ranked in the top 37% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Company Overview - Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation in the biopharmaceutical industry, founded in 1996 [2] - The company collaborates with innovators from academic institutions, research hospitals, non-profits, and biopharmaceutical companies, funding innovation directly and indirectly [2] - Royalty Pharma's portfolio includes royalties on over 35 commercial products and 17 development-stage product candidates, such as Vertex's Trikafta, GSK's Trelegy, Roche's Evrysdi, and others [2] Leadership Appointment - Molly Sawaya has been appointed as Executive Vice President, Head of Human Capital at Royalty Pharma [4] - Molly brings nearly 15 years of HR experience from large global organizations, including Hudson Bay Capital, QBE Insurance Group, Perpetual Limited, and National Australia Bank [1][8] - Her role will focus on fostering a culture of growth and supporting the scaling of the business [8] Business Model - Royalty Pharma funds innovation directly by partnering with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties [2] - Indirectly, the company acquires existing royalties from original innovators, building a portfolio tied to the top-line sales of leading therapies [2]